期刊文献+

颈动脉斑块类型与MMP-9的相关性研究 被引量:7

Relationship between MMP-9 and different types of carotid plaque
下载PDF
导出
摘要 目的通过对不同类型颈动脉斑块患者进行分型并检测其血浆基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)水平,来观察颈动脉斑块易损性与MMP-9的相关性。方法对64例颈动脉斑块患者行颈部血管B超、TCD、头颅CT、MRI、DSA检查及神经功能评分(NIHSS),对患者颈动脉斑块进行分型,并检测其血浆MMP-9、C-反应蛋白(CRP)水平。结果血浆MMP-9水平与斑块易损性呈正相关(r=0.92,P<0.01),即血浆MMP-9水平越高,斑块的稳定性越低。CRP在实验组显著高于对照组,实验组中B、C组显著高于A组(P<0.01),而B组和C组比较无统计学意义(P>0.05),提示CRP在颈动脉斑块的患者会升高,但它与颈动脉斑块的易损性的相关性不如MMP-9。结论颈动脉斑块易损性与血浆MMP-9水平呈正相关。我们可以通过影像学及临床检查结合血浆MMP-9水平来判断颈动脉斑块易损性。MMP-9作为易损斑块的潜在血清标志物,在缺血性脑血管病的预防、诊断和治疗上有积极的临床意义。 Objective To observe blood plasma matrix metalloproteinase-9 (MMP-9) of the patients with different types of carotid plaque and investigate the relationship between MMP-9 and carotid plaque vulnerability. Methods Totally 64 patients were examined by CDI, TCD, cranium CT, MRI, DSA and nerves function score (NIHSS) to judge their types of carotid plaque. Their plasma levels of MMP-9 and C-reactive protein (CRP) were detected. Results Plasma MMP-9 had direct correlation with plaque vulnerability(r =0. 92 ,P 〈 0. 01 ), viz, the higher blood plasma MMP-9 level, the more vulnerable of the plaque was. Plasma CRP in carotid plaque group was significantly higher than those in health individuals, and those of patients with vulnerable and to-be-vulnerable plaque were higher than those of patients with non-vulnerable plaque ( P 〈 0. 01 ), but there was no statistically significant between the former 2 groups. Conclusion There is a direct correlation of plasma MMP-9 with carotid plaque vulnerability. Carotid plaque vulnerability can be decided by imageology, clinical examination as well as plasma MMP-9 level. MMP-9 can be regarded as latent serum marker of vulnerable plaque, and has clinical significance in synteresis, diagnosis, and therapy of ischemic cerebrovascular disease.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2007年第18期1812-1814,共3页 Journal of Third Military Medical University
关键词 缺血性脑血管病 基质金属蛋白酶-9 C-反应蛋白 ischemic cerebrovascular disease matrix metalloproteinase-9 C-reactive protein
  • 相关文献

参考文献13

  • 1Libby P.Changing concepts of atherogenesis[J].J Intern Med,2000,247(3):349-358.
  • 2单岩,徐析,单菲.血清MMP-2,MMP-9水平对急性冠脉综合征的诊断及预后判断价值[J].第三军医大学学报,2005,27(18):1909-1909. 被引量:5
  • 3Loftus I M,Naylor A R,Goodall S,et al.Increased matrix metalloproteinase-9 activity in unstable carotid plaques.A potential role in acute plaque disruption[J].Stroke,2000,31(1):40-47.
  • 4Mori T,Fukuoka M,Kazita K,et al.Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty[J].AJNR Am J Neuroradiol,1998,19(8):1525-1533.
  • 5Jimenez C,Duong H,Olarte M,et al.Recurrent abrupt occlusion after transluminal angioplasty for basilar artery stenosis:case report[J].Neurosurgery,1999,44(1):210-215.
  • 6Beaudeux J L,Giral P,Bruckert E,et al.Matrix metalloproteinases,inflammation and atherosclerosis:therapeutic perspectives[J].Clin Chem Lab Med,2004,42(2):121-131.
  • 7Crisby M,Nordin-Fredriksson G,Shah P K.Pravastatin treatment increases collagen content and decreases lipid content,inflammation,metalloproteinases,and cell death in human carotid plaques:implications for plaque stabilization[J].Circulation,2001,103(7):926-933.
  • 8Ferroni P,Basili S,Mattini F,et al.Serum metalloproteinase 9 levels in patients with coronary artery disease:a novel marker of inflammation[J].J Investig Med,2003,51(5):295-300.
  • 9Reynolds M A,Kirchick H J,Dahlen J R,et al.Early biomarkers of stroke[J].Clin Chem,2003,49(10):1733-1739.
  • 10Kalela A,Koivu T A,Sisto T,et al.Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease[J].Scand J Clin Lab Invest,2002,62(5):337-342.

二级参考文献22

  • 1Biasucci L M, Liuzzo G, Grillo R L, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability [J]. Circulation, 1999, 99 (7): 855 - 860.
  • 2Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 1998, 32(2): 368 -372.
  • 3Pifarre R, Scanlon P. Evidence based management of the acute coronary syndrome. Philadelphia: Hanley & Belfus,Inc, 2001..
  • 4Radomski A, Stewart MW, Jurasz P,et al. Pharmacological characteristics of solid-phase von Willebrand factor in human platelets. Br J Pharmacol,2001,134(5 ): 1 013.
  • 5Kuzuya M, Kanda S, Sasaki T, et al. Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation,2003,108(11):1 375.
  • 6Blankenberg S, Rupprecht H J, Poirier O, et al. Plasma concentrations and genetic variation metalloproteinase-9 and prognosis of patients with cardiovascular disease. Circulation,2003,107(12) :1 579.
  • 7Solymoss BC, Bourassa MG, Lesperance J, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis,2003,14(13) :207.
  • 8Garber AJ. Attenuating cardiovascular risk factors in patients with type 2 diabetes. Am Fam Physician,2000, 62 (12):2 633.
  • 9Antaman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA,2000, 284(7) :835.
  • 10Garcia S, Canoniero M, Peter A, et al. Correlation of TIMI risk score with angiographic severity and extent of coronary artery disease in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol,2004,93: 813.

共引文献7

同被引文献78

引证文献7

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部